lyj19721101 2015-03-13 14:16 IP:马鞍山
弥漫性大B细胞淋巴瘤(DLBCL)是一种最常见的非霍奇金淋巴瘤,诊断病例在美国约占淋巴瘤的30%。它是一种特异质性疾病。由于临床多样性和复杂性,又有新的突变在某些难治性患者身上被发现。阿斯利康需要创建一种弥漫性巨大B细胞淋巴瘤的合适的临床模型。 具体链接在:https://www.innocentive.com/ar/challenge/9933016 AstraZeneca Challenge: Developing Clinically-Relevant Models for Diffuse Large B Cell Lymphoma (DLCBL) TAGS: AstraZeneca, Physical Sciences, Life Sciences, Nature, Requests for Partners and Suppliers, Chemistry, RTP AWARD: See details | DEADLINE: 6/02/15 | ACTIVE SOLVERS: 9 | POSTED: 3/04/15 Diffuse large B cell lymphoma (DLBCL) is the most common form of non-Hodgkin lymphoma and accounts for up to 30% of newly diagnosed cases in the United States. It is a heterogeneous disease which in part appears to be driven by chronic activation of key survival pathways. A limited number of DLBCL cell lines are available, however there are gaps, and specific patient subtypes are not represented. To add to the complexity of clinical diversity, new mutations are being identified in certain treatment-resistant patients. AstraZeneca is interested in innovative proposals to create suitable preclinical models of DLBCL. This is a Reduction-to-Practice Challenge that requires a written proposal and experimental proof-of-concept data (and/or sample delivery). The Challenge has a special award structure. Whether creating a model for DLBCL or a model of acquired resistance to ibrutinib, up to $10,000 will be designated for solutions that highlight novel technologies to generate in vitro cell lines, whereas up to $25,000 will be awarded for submissions that successfully utilize patient-derived tissues.   [更多]
悬赏:
悬赏
¥90000.00
载入中...
zhangyangoil 2022-03-01 14:25 IP:武汉
甲基多巴  METHYL DOPA  CAS 555-30-6求购:原料药 甲基多巴的商业化生产工艺,非专利网的文献。有实际完整生产工艺的可以详谈!甲基多巴是一种抗高血压药,为白色或类白色结晶性粉末;无臭。其主要是在中枢转化成甲基去甲肾上腺素。甲基去甲肾上腺素是一种很强的中枢α2受体激动药。用于中、重度或恶性高血压,还有镇静、降低眼压作用。   [更多]
悬赏:
悬赏
¥80000.00
载入中...
zhangyangoil 2022-03-01 14:29 IP:武汉
求购 苯磺顺阿曲库铵 原料药 商业化生产工艺!Q2736068151苯磺顺阿曲库铵(cisatracurium besylate)是最新一代肌松剂,广泛应用于气管 插管、肝肾功能障碍、心血管手术等领域。苯磺酸阿曲库铵有4个手性中心,10个同分异构体,分子中含有4个手性中心,其中2个为手性碳,2个为手性氮,顺苯磺阿曲库铵为1R,1'R,2R,2'R异构体。我方需求顺苯磺阿曲库铵大生产合成工艺,要求整个工艺有较好的选择性,反应的收率和产品的纯度较高。我司需要商业化生产工艺而不是 专利网文献,需求真实有效,可提供者可私聊!   [更多]
悬赏:
悬赏
¥80000.00
载入中...
雨suv 2011-11-25 15:26 IP:运城
  富马酸酮替芬原料工艺,要求工艺成熟,标准EP   [更多]
悬赏:
悬赏
¥50000.00
载入中...
wu317823680 IP:重庆
求五水头孢唑林钠原料药合成工艺,有的请回复!   [更多]
悬赏:
悬赏
¥50000.00
载入中...
sssssssss 2019-10-21 17:52 IP:重庆
用于获得性免疫缺陷综合征(AIDS)患者巨细胞病毒(CMV)性视网膜炎,在海外已经上市,规格450毫克   [更多]
悬赏:
悬赏
¥50000.00
载入中...
lyj19721101 2015-06-19 15:47 IP:马鞍山
肝脏疾病是一种由病毒或有毒物连续侵害造成肝脏晚期纤维化的慢性疾病。目前,我们的治疗方法很有限,寻找治疗方法的大多数临床试验都失败了,部分原因是由于缺乏预测肝脏疾病发展的生物标志物。公司需要寻找一种新的生物标志物,对提高疾病的可控性会有很大的帮助,定期监测生物标志物也可以促进临床试验治疗药物的进一步发展。 具体可以查看https://www.innocentive.com/ar/challenge/9933671 Challenge Overview Liver disease represents a worldwide unmet medical need. Although there are various causes, the danger is that the liver will become so damaged that it can no longer function adequately. Whether the insult is a viral infection, chemical injury, or immune-related, liver disease follows a slow and steady progression. Early stage liver disease is characterized by inflammation, which if left untreated, can cause scarring and fibrosis. A healthy liver is capable of repair and regeneration, but when there are architectural changes to the tissue, the damage can no longer be reversed. Biopsies are routinely conducted to diagnose liver fibrosis and cirrhosis. Undergoing this invasive procedure involves significant abdominal pain along with the risk for complications and sampling error. Therefore, many patients are reluctant to have a second biopsy even when it is medically advisable. The Seeker desires a specific and sensitive biomarker(s) that is highly associated with liver fibrosis and could be used as a surrogate for clinical efficacy and ideally, could guide treatment selection. Submissions to this Challenge must be received by 11:59 PM (US Eastern Time) on August 17, 2015. Late submissions will not be considered. This is a Theoretical Challenge that requires only a written proposal to be submitted. The Challenge award will be contingent upon theoretical evaluation of the proposal by the Seeker. To receive an award, Solvers will not be required to transfer their exclusive IP rights to the Seeker. Instead, as further described in the Challenge-Specific Agreement, Solvers will grant to the Seeker a one hundred and eighty (180)-day Exclusivity Period from the deadline [11:59 PM (US Eastern Time) on August 17, 2015] for a non-exclusive   [更多]
悬赏:
悬赏
¥50000.00
载入中...
del826706212 2017-08-09 09:03 IP:重庆
我需要全球或全国的药品制剂(分剂型规格)销售数据,数据包括通用名、商品名、生产 厂家、销售额销售量等等,寻找可以长期提供全球或全国的药品制剂(分剂型规格)销售 数据的合作者,全球或全国的药品制剂(分剂型规格)销售数据详细完整并且数据真实可靠。 如果能长期提供该数据的,请投稿,具体价格等事宜单独联系。 投稿留下联系方式,本人会定期来关注的。   [更多]
悬赏:
悬赏
¥50000.00
载入中...
13612807752 2016-01-21 10:46 IP:深圳
对照品合成提供信息 1. 提供合成工艺起始原料名称、中间体或粗品。 2. 提供合成工艺中最后三步所用的有机溶剂名称。 3. 提供质谱、核磁定性结果。(要解析) 4. 纯度要求达到95%,有图谱确认。   [更多]
悬赏:
悬赏
¥50000.00
载入中...
佩奇智慧 2019-08-14 14:51 IP:未知
药智新闻平台面向广大医药人,招募专栏作家,长期有效。 要求:1.笔锋强劲,对圈内热点嗅觉敏感; 2.医药圈的犀利点评家、深度解读者、内幕爆料人,对人对事有着独到的见解与看法; 3.原创,药智网首发,字数限制在3000以上,论据支撑严谨等; 联系方式:QQ:2108599521、邮箱:2108599521@qq.com   [更多]
悬赏:
悬赏
¥50000.00
载入中...
发布需求,坐等药智客上门
  • 安全可靠,先验收再正式付款
  • 性价比超高,节省一半费用
  • 80%的需求得到了圆满解决
立即发布需求

推荐任务